Meeting
2018 Gastrointestinal Cancers Symposium
Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D).
Authors
Yung-Jue Bang
Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
Yung-Jue Bang , Talia Golan , Chia-Chi Lin , Yoon-Koo Kang , Zev A. Wainberg , Heather Wasserstrom , Jin Jin , Gu Mi , Samuel McNeely , Naomi Laing , Laura Williams Goff , Siqing Fu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02572687
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 92)
DOI
10.1200/JCO.2018.36.4_suppl.92
Abstract #
92
Poster Bd #
G20
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
An open-label, single-arm, dose escalation and expansion phase 1 study of tebotelimab (MGD013) plus niraparib in patients with locally advanced or metastatic gastric cancer who failed prior treatments.
First Author: Miaozhen Qiu
Poster
2021 ASCO Annual Meeting
BEGONIA: Phase 1b/2, open-label, platform study of the safety and efficacy of durvalumab (D) ± paclitaxel (P) with novel oncology therapies for first‑line metastatic triple-negative breast cancer (mTNBC): Addition of arm 7, D + datopotamab deruxtecan (Dato-DXd; DS-1062).
First Author: Peter Schmid
Poster
2021 ASCO Annual Meeting
BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).
First Author: Peter Schmid
Poster
2018 ASCO Annual Meeting
A phase 2 study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (TIL, LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab in patients with locally advanced or metastatic NSCLC.
First Author: Sylvia Mina Lee